一次情報の記録
重要提携・ライセンス契約
SpyGlass Pharma Acquires AVS from Santen to Secure IOL Manufacturing for BIM-IOL System
SpyGlass Pharma acquired 100% of Advanced Vision Science, Inc. (AVS), its current IOL manufacturer and a former Santen subsidiary, for ~$13M. The deal secures scalable commercial manufacturing capacity for the Phase 3 BIM-IOL System and accelerates development of premium lens options (toric, EDOF) integrated with its drug-delivery platform. AVS will continue supplying Santen in Japan and licensing material to Bausch + Lomb and others.
主要事実
- 提出
- 2026年10月1日 12:15
- イベント
- 提携・ライセンス契約
- 方向
- ポジティブ
- アセット
- bimatoprost
- 出典
- SEC 8-K
- 信頼度
- 出典あり
- 買収コスト
- 約1300万ドル
出典の抜粋
EX-99.1 2 exhibit991-8kprx100126.htm EX-99.1 Document Exhibit 99.1 SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability • SpyGlass Pharma acquires 100% of the outstanding shares of AVS, a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), the existing manufacturer of SpyGlass Pharma’s intraocular lens (IOL) • Secures scalable commercial IOL manufacturing capacity for its Phase 3 lead product candidate, the BIM-IOL System • Accelerates pathway to adding premium lens options into its IOL-based drug delivery system • SpyGlass Pharma intends to continue supporting AVS customers and licensees utilizing their proprietary IOL material technology, such as Santen, Bausch + Lomb, and other g